Furosemide-Associated Risks and Monitoring Requirements

Electrolyte and Metabolic Disturbances

Hypokalemia occurs in approximately 3.6% of patients, particularly with brisk diuresis, inadequate oral electrolyte intake, cirrhosis, or concurrent use of corticosteroids, ACTH, or laxatives, according to the American College of Cardiology 1
Metabolic alkalosis frequently accompanies electrolyte depletion and can exacerbate CO2 retention in patients with chronic lung disease, as reported by the American Journal of Respiratory and Critical Care Medicine 2
The risk of electrolyte depletion is markedly enhanced when two diuretics are used in combination, as enhanced sodium delivery to distal tubules increases cation exchange, a process potentiated by renin-angiotensin-aldosterone system activation, according to the American College of Cardiology 1, 3
Concomitant administration of ACE inhibitors or potassium-sparing agents like spironolactone can prevent electrolyte depletion and often eliminates the need for long-term oral potassium supplementation, as recommended by the American College of Cardiology 1, 3

Hypotension and azotemia can result from excessive diuretic use, impairing renal function and exercise tolerance, according to the American College of Cardiology 1, 3
Initial hemodynamic worsening may occur with IV administration, including orthostatic hypotension, transient decrease in stroke volume, and increased systemic vascular resistance, which can be managed with diuretic dose reduction, as suggested by the American College of Cardiology 1, 3

Transient or permanent hearing loss can occur, particularly with rapid IV administration of high doses (>6 mg/kg/day) or when used concomitantly with other ototoxic drugs, as reported by the American Journal of Respiratory and Critical Care Medicine and Nature Reviews Nephrology 2, 4
High-dose furosemide (>6 mg/kg/day) should not be given for periods longer than 1 week, and infusions should be administered over 5-30 minutes to avoid hearing loss, as recommended by Nature Reviews Nephrology 4

Nephrocalcinosis and nephrolithiasis occur with long-term use, particularly in premature infants, requiring monitoring of renal function and renal ultrasonography, as reported by the American Journal of Respiratory and Critical Care Medicine 2
Hypercalciuria leads to nephrocalcinosis risk, according to the American Journal of Respiratory and Critical Care Medicine 2

NSAIDs (including COX-2 inhibitors) can block diuretic effects and cause increased BUN, serum creatinine, potassium levels, and weight gain, as reported by the American College of Cardiology 1

The American Thoracic Society notes that long-term use of furosemide increases the risk of nephrolithiasis, particularly in premature infants, and requires monitoring of renal function and renal ultrasonography 5, 6

The American College of Cardiology recommends caution with IV administration of furosemide, as it may cause initial worsening of hemodynamics, including orthostatic hypotension, transient decrease in stroke volume, and increased systemic vascular resistance 7